NEW YORK, Aug. 11 /PRNewswire/ -- Mergent, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange Traded Funds, today announced the following change effective on the opening of trading on Thursday August 14, 2008: Biotest AG (Frankfurt, Germany: BIO) will replace Speedel Holding AG (SWX, Switzerland: SPPN) in the HealthShares(TM) European Drugs Index. Speedel Holding AG is being acquired by Novartis AG (SWX, Switzerland: NOVN).
Companies included in the HealthShares(TM) European Drugs Index are headquartered in Europe and quoted on at least one European Stock Exchange that are engaged in the research, clinical development, manufacturing and commercialization of pharmaceutical products, small molecule/chemical moieties, biologics (proteins, peptides, oligoneucleotides, and cell/gene therapies) and vaccines, in all therapeutic categories, primarily intended for humans.
Mergent, Inc. is a leading provider of business and financial data on global publicly listed companies. Based in the U.S., the company maintains a strong global presence, with offices in New York, Charlotte, San Diego, London, Tokyo and Melbourne.
Founded in 1900, Mergent operates the longest continuously collected
database of: descriptive and fundamental information on domestic and
international companies; pricing and terms and conditions data on fixed
income and equity securities; and corporate action data. In addition,
Mergent develops and licenses equity and fixed income investment products
based on its proprietary investment methodologies. Mergent-licensed
products have approximately $3.5 billion in assets under management and are
offered by major investment management firms. Mergent's index calculation
platform is the chosen techn
|SOURCE Mergent, Inc.|
Copyright©2008 PR Newswire.
All rights reserved